Palliative Care at Home for Dementia

Sponsor
Icahn School of Medicine at Mount Sinai (Other)
Overall Status
Completed
CT.gov ID
NCT03798327
Collaborator
National Institute on Aging (NIA) (NIH)
41
4
2
41.9
10.3
0.2

Study Details

Study Description

Brief Summary

The proposed project is a randomized controlled trial of a new home-based palliative care program for adults with advanced dementia and their caregivers within the Mount Sinai Health System. Potential subjects will be identified from Mount Sinai records or referred by a Mount Sinai healthcare provider. Patients will only be approached after authorization by their Mount Sinai physician. Participants who consent to enrollment will be randomized to receive the intervention (home-based palliative care program) or usual care (with their nominated Mount Sinai physician). Patients will be enrolled in the study for 6 months.

Effectiveness of the intervention will be determined through assessment of patient and caregiver reported outcomes and abstraction of data from medical records and administrative claims. Impact on the following parameters will be measured: (i) Patient symptoms, quality of life, satisfaction with care, documentation of advanced directives, receipt of care consistent with preferences (ii) Caregiver burden, satisfaction with care, and depression (iii) Healthcare utilization and costs of care.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Home Palliative Care
N/A

Detailed Description

The objective of this randomized controlled trial is to study the impact of a new home based palliative care program on patients' symptoms, quality of life, satisfaction with care, completion of advance care planning documentation and receipt of care consistent with preferences. In addition, the study will examine the impact of this model of care on patient healthcare utilization, including hospitalization, emergency department utilization, and hospice use prior to death. The trial will also include patients' caregivers, in order to examine the impact of the intervention on caregiver burden and prevalence of depression.

Patients randomized to the intervention will be scheduled for an intake visit. This visit will be undertaken by the team's registered nurse and/or social worker, together with a community health worker, and other team members (advanced practice nurse, MD), depending on patients' needs. Visits will combine a combination of video-teleconferencing technology and in person visits. Following this visit, and in conjunction with the nurse practitioner and/or MD, a care plan will be developed to address areas of clinical need highlighted during the intake visit.

Patients in the intervention arm will receive ongoing monitoring and input (telephone-based, video-based, and in-person) from members of the clinical team, dependent on their identified needs. Patients' cases will be discussed at the weekly IDT meeting, as appropriate to the level of clinical need. Patients and caregivers will be provided with access to a 24 hour telephone line, staffed by a Mount Sinai based physician, which acts as an advice line out of hours. These physicians will be able to provide advice to patients and caregivers.

Study Design

Study Type:
Interventional
Actual Enrollment :
41 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
Single blind control
Primary Purpose:
Health Services Research
Official Title:
Video-Assisted Palliative Care Intervention for Patients With Advanced Dementia at Home
Actual Study Start Date :
Nov 1, 2018
Actual Primary Completion Date :
Apr 29, 2022
Actual Study Completion Date :
Apr 29, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Home Palliative Care

Randomized to Intervention Arm

Behavioral: Home Palliative Care
Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.

No Intervention: Control Arm

Usual Care - Patients will be cared for by the physician who treats their dementia and other illnesses.

Outcome Measures

Primary Outcome Measures

  1. Symptom Management at the End of Life for Dementia scale [6 months]

    This will be determined using a validated structured questionnaire administered to patient-subjects or caregiver via telephone interview or in person by the trained research coordinator Scale: Symptom Management at the End of Life for Dementia - Likert scale, 9 items, each 0-5, (45 total possible score) higher is worse symptoms

Secondary Outcome Measures

  1. Patient Quality of Life - Alzheimer's Disease scale [6 months]

    This will be determined using a validated structured questionnaire administered to patient-subjects or caregiver via telephone interview or in person by the trained research coordinator. Scale: Quality of Life - Alzheimer's Disease; Likert scale, 13 items, each 1-4, (52 total possible score) lower is worse quality of life

  2. Number of Complete of Advance Directives [6 months]

    The Study Team will examine the patient's chart for completion of advanced directives Scale: Study Team will examine the patient's chart for completion of advanced directives (yes/no).

  3. Preference Consistent Care [6 months]

    The Study Team will examine if the care patients receive is concordant with the care they wanted to receive. Scale: Simple chart review of whether care received matches stated preferences (yes/no)

  4. Caregiver Zaria Burden Inventory [6 months]

    Zarit Burden Inventory to determine caregiver burden by using a validated structured 22-item questionnaire administered to caregiver-subjects via telephone interview or in person by the trained research coordinator. Each item is on a 5-point scale range from 0 (never) to 4 (always) Scale: Zarit Burden Inventory - Likert scale 0-4,total score = 0-88, higher score is more burden

  5. Caregiver FAMCARE-10 [6 months]

    FAMCARE-10 to assess caregiver satisfaction by using a validated 10-item structured questionnaire administered to patient-subjects via telephone interview or in person by the trained research coordinator. Scale: FamCare; Likert scale, 0-3, higher is higher satisfaction

  6. Caregiver PHQ-9 [6 months]

    PHQ-9 to assess Caregiver Depression by using a validated structured 9 item questionnaire administered to caregiver-subjects via telephone interview or in person by the trained research coordinator. The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as "0" (not at all) to "3" (nearly every day). Scale: Patient Health Questionnaire - 9; Likert scale, 0-3, total possible = 0-27; higher is worse depression [Time Frame: 6 months]

  7. Number of hospital admissions [6 months]

    healthcare utilization

  8. Number of emergency department visits [6 months]

    healthcare utilization

  9. Number of outpatient appointments [6 months]

    healthcare utilization

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Presence of advanced dementia

  • Subject has a Mount Sinai physician who authorizes their participation in the study and receipt of the program

  • Subject is resident in Manhattan outside of a long term care facility and is not receiving hospice 5.

  • Subject has evidence of capacity to benefit from enrollment in palliative care program

  • Subject is conversant in English or Spanish

  • Subject has capacity to consent or has a caregiver who can provide consent for the patient

Exclusion Criteria:
  • Subject has no usual physician within Mount Sinai

  • Subject's usual physician doesn't provide authorization to patient participation

  • Subject resident outside of Manhattan or in long term care facility or receiving hospice

  • Subject is not conversant in English or Spanish

  • Subject cannot provide consent or has no caregiver who can provide consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mount Sinai Beth Israel New York New York United States 10003
2 Mount Sinai West New York New York United States 10019
3 Mount Sinai St. Luke's New York New York United States 10025
4 Icahn School of Medicine at Mount Sinai New York New York United States 10029

Sponsors and Collaborators

  • Icahn School of Medicine at Mount Sinai
  • National Institute on Aging (NIA)

Investigators

  • Study Director: Nathan Goldstein, MD, Icahn School of Medicine at Mount Sinai

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nathan Goldstein, Professor, Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier:
NCT03798327
Other Study ID Numbers:
  • GCO 17-02787
  • R56AG067045-01
First Posted:
Jan 9, 2019
Last Update Posted:
Aug 1, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Nathan Goldstein, Professor, Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 1, 2022